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ALTERED SEXUAL MATURATION IN MALE RATS PASSIVELY IMMUNIZED AGAINST rGRF FROM 1 5 TO 4 0 DAYS OF L I F E GH d e p r i v a t i o n f o l l o w i n g p a s s i v e lmmunizatiori ( P I ) a g a l n s l r G W markedly a f f e c t s s o m a t l c yrowth i n r a t s . S l n c e i t h a s b e e n p o s t u l a t e d t h a t GH and p r o b a b l y IGF-I h a v e a p e r m i s s i v e r o l e on s e x u a l m a t u r a t i o n , t h e e f f e c t of GI1 d e p r i v a t i o r i on t h e c o u r s e
Of s e x u a l m a t u r a t i o n was t e s t e d . M a l e r a t s w e r e t -r e a t e d w l t h a p o t e n t a n t i -r G W serum between 15 and 4 0 d a y s o f l i f e ( d ) . Body w e i g h t (BW) o f t r e a t e d r a t s a v e r a g e d 7 6 . 3 % of t h a t of c o r i t r o l r a t s a t 4 0 d and was m a x i m a l l y a f f e c t e d a t 5 0 d ( 5 6 . 9 % ) a f t e r w h i c h a g e , t r e a t e d r a t s s t a r t e d t o grow n o r m a l l y . At 4 0 and 5 0 d , plasma GH was u n d e t e c t a b l e and p l a s m a IGF-I l e v e l s a v e r a g e d 3 0 % o f t h o s e o f c o n t r o l r a t s . A t 7 0 d , GI1 & I G F -I s e c r e t i o n s were normal. At 4 0 d , t e s t e s a n d s e m i n a l v e s i c l e s o f t r e a t e d r a t s w e r e s m a l l -f o r -a y e i n a g r e e m e n t w i t h s l g n l f i c a n t l y d e c r e a s e d p l a s m a l e v e l s o f t e s t . o s t . c r o n e a n d FSH. A t 5 0 d , d e s p i t e maximum d e l a y o f s o m a t i c g r o w t h , p r o y r e s s o f s e x u a l m a t u r a t i o n w a s f o u n d t o b e a l m o s t n o r m a l . A t 4 0 a n d 5 0 d , p i t u i t a r y w e i g h t a n d c o n t e n t s of G H , FStl, and L l l were s e v e r e l y d e c r e a s e d b u t b e c a m e n o r m a l a t 7 0 d . I n c o n c l u s i o n , GH d e p r i v a t i o n m a r k e d l y a f f e c t e d s o r n a t l c g r o w t i ) a n d i n d u c e d a t r a n s i e n t d e l a y o f s e x u a l m a t u r a t i o n s e c o n d a r y t o a p a r t i a l inhibition o f s y n t h e s i s and r e l e a s e of LH & FSll. T h i s i n h i t r l t i o n o f LH & FSH s e c r e t i o n may r e s u l t from c e n t r a l i n h i b i t i o n o f GnRli s e c r e t i o n o r froni i m p a~. r e d d e v e l o p m e r~t of t h e p i t u i t a r y g l a n a .
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The availability for clinical use o f somatocrinine growth hormone releasing hormone ( G R F I brings about the possibility of treatment of growth hormone deficient children (GHD) of hypothalamic origin. We present the results of the flrst 6 months of treatment o f G R F in 2 0 G H D children. Ten boys and 1 0 girls w i t h mean chronological age of 10.7 f2.7 yr, bone age 6.1 2.5 ,,yr" and w i t h a mean growth retardation o f 4.7 f 0.6 SD were treated w i t h G R F 1 -4 4 S A N O F I b y daily ( N = 11) or thrice weekly ( N = 91 sukutaneous injection i n doses o f 1 0 u g l k g body weight. A l l o f the c h~l d r e n were i n prepubertal stage and i n all the peak G H response t o clonidine and I'dopa provocative tests was h l o w 5 nglml. Nlne patients had TSH deflclency and were parallely treated w i t h I'thyroxine. The G R F i.v. bolus test was performed before treatment and 2 and 6 months after initiation of treatment. I n 9 out of 2 0 patients acceleration o f growth velocity was found. Three patients reached a growth velocity o f more than 4.4 c m per yr. Growth velocity during the treatment was significantly correlated w l t h peak G H response t o G R F i.v. bolus before (r-0.67861 and during the treatment (r=0.4863 and r -0.5947, respectively). The growth velocity was greater i n younger children and i n those w i t h less advanced bone age. Acute response t o G R F was significantly greater after 6 months o f treatment than before the treatment (mean peak G H response 2.9 f 3.0 and 7.6 + 8 . l n g l m l respectively, p <0.05).
N o side effects o f the treatment were observed and immunological tolerance was good. We concluded that chronic administration of G R F is well tolerated and resulted i n enhanced growth i n some o f the G H D children and evoked better response of somatotrophs t o G R F i.v. bolus In a previws work we demxlstrated that in adults timing of G3Ul stlrmlaticn i n relation t o the patkm of spontanecus G I secretion cculd condition M respx%?.To investigate i f there was a similar s i b t l c n i n children,a GW test (5F-29,Semo 1 mcg/kg,iv b o l u s ) was performed i n 17 SN (@1,9F,7-11 y) and 6 0iT ( 3 , 3 F , E -12 y) a t 09.3 h a f t e r an ovenu&t f a s t and 33' resting.Fmn the analysi:; of p l m 0 i variations (-33',01) prior t o s t i m l a t i c n , 3 theoretical pha%es in t 6 R were estab1ished:A)Secmtim Ph3se;B)Secretion F1ateau;C)Refractory Phase, (see f i g . ) .Qi peak after W-29 was evaluated according t o the theoretical phase a t testing.PE3LTS ( x m ) . -A very hi& correlation (Spearman's t e s t )
was obtained between pre-CdiF 01 i n c m n t s (+,-o r 0 ) and 81 r & in SN (14.81, p(O.WJ1) .No differences w e found in the distribution per phase between W and F SN. (Gtng/ml). identical in all p;roups (peak Cal 15-75 mim) alt,tn@ Qideficient, pat.ient.s b d s w f i c a n t l y l m r M mponses t h the m& subjects. A11 pt,ient pro~ps skwd a s m f i c a n t l y greater Q1 r e s p x~ after BW1 than hxzqJycaemia. In particular, in IS5 the M respcvlse t o QlRH cas ident,ical t,o t k t of n o m d sub.Wts and s i q i f i c a n t l y grY-ater tkvl t h e i r resporrse t o t , k I'IT (p:0.011). The Endocrine U n i t , The Eiiddleaex I l o s p i t a l , London W1 U n i t e d Kingdom.
CONTINUOUS S.C. INFUSIONS OF GLIRH ANAI.OGUE CllRil(l-29) W
NOT DESENSITIZE TIIT. SOMATOTROPII.
We have shown t h a t CHRII n d m i n l a t e r e d subcutaneot~sly i n a p u l s a t i l e f a s h i o n i s e f f e c t i v e i n t h e treatment of GI1 d e f i c i e n y . GI1 s e c r e t i o n was not augmented b y doses o f 7.5 and 15nglkg/min. W i t h 30nglkglmin s i g n i f i c a n t i n c r c n s e s i n GI! p u l s e frequency and a m p l i t u d e were achieved w i t h normal p r o f i l e s .
Doses of 60 and 120nglkg/min induced h i g h p u l s e frequency (up t o 1 3 pulses124 h ) and we know from c l i n i c a l s t u d i e s t h a t GI1 n e u r o s c c r e t o r y d y s f u n c t i o n ( > 9 pulses124 11) f a i l s t o produce adequate growth. 12Onglkglmin a l s o produced v e r y h i g h GH pedhs (max 122mUIL) which f a i l e d t o r e t u r n t o t h e b a s e l i n e between pulses, an abnormal p u l s e p r o f i l e .
There has been no evidence o f d e s e n s i t i z a t i o n o f t h e h y p o t l l a l a m o -p i t u i t x y axis a t any dose o v e r one week. Wl~ell~er suclt a p a t t e r n r c r l e c t s an a l t e r a t i o n i n h y p o l l~a l a n i c o r p i t u i t a r y mccl~anisms i s unknoun.ln thc p r c s e n t study vc i n v e s t i g a t e d GI1 response t o i.v. 
